KR20210043635A - B 세포 악성 종양의 치료 - Google Patents

B 세포 악성 종양의 치료 Download PDF

Info

Publication number
KR20210043635A
KR20210043635A KR1020217007417A KR20217007417A KR20210043635A KR 20210043635 A KR20210043635 A KR 20210043635A KR 1020217007417 A KR1020217007417 A KR 1020217007417A KR 20217007417 A KR20217007417 A KR 20217007417A KR 20210043635 A KR20210043635 A KR 20210043635A
Authority
KR
South Korea
Prior art keywords
compound
mixture
alkyl
heterocyclyl
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020217007417A
Other languages
English (en)
Korean (ko)
Inventor
다니엘 피 골드
Original Assignee
메이 파마, 아이엔씨.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 메이 파마, 아이엔씨. filed Critical 메이 파마, 아이엔씨.
Publication of KR20210043635A publication Critical patent/KR20210043635A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
KR1020217007417A 2018-08-14 2019-08-13 B 세포 악성 종양의 치료 Ceased KR20210043635A (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862718929P 2018-08-14 2018-08-14
US62/718,929 2018-08-14
US201862775797P 2018-12-05 2018-12-05
US62/775,797 2018-12-05
US201962836511P 2019-04-19 2019-04-19
US62/836,511 2019-04-19
PCT/US2019/046411 WO2020036999A1 (en) 2018-08-14 2019-08-13 Treatment of b cell malignancies

Publications (1)

Publication Number Publication Date
KR20210043635A true KR20210043635A (ko) 2021-04-21

Family

ID=69525845

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217007417A Ceased KR20210043635A (ko) 2018-08-14 2019-08-13 B 세포 악성 종양의 치료

Country Status (14)

Country Link
US (1) US20210299134A1 (https=)
EP (1) EP3836935A4 (https=)
JP (1) JP2021534115A (https=)
KR (1) KR20210043635A (https=)
CN (1) CN112888441A (https=)
AU (1) AU2019321432A1 (https=)
BR (1) BR112021002760A2 (https=)
CA (1) CA3109184A1 (https=)
IL (1) IL280726A (https=)
MA (1) MA53236A (https=)
MX (1) MX2021001606A (https=)
SG (1) SG11202101450VA (https=)
TW (1) TW202021591A (https=)
WO (1) WO2020036999A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2608967T3 (es) 2011-03-28 2017-04-17 Mei Pharma, Inc. (Aralquilamino sustituido en alfa y heteroarilalquilamino)pirimidinil y 1,3,5-triazinil benzimidazoles, composiciones farmacéuticas que los contienen, y estos compuestos para usar en el tratamiento de enfermedades proliferativas
US11304953B2 (en) 2017-05-23 2022-04-19 Mei Pharma, Inc. Combination therapy
KR20200041358A (ko) 2017-08-14 2020-04-21 메이 파마, 아이엔씨. 병용 요법

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2648676A4 (en) * 2010-12-06 2016-05-04 Follica Inc METHODS FOR TREATING CALVITIA AND PROMOTING HAIR GROWTH
ES2608967T3 (es) * 2011-03-28 2017-04-17 Mei Pharma, Inc. (Aralquilamino sustituido en alfa y heteroarilalquilamino)pirimidinil y 1,3,5-triazinil benzimidazoles, composiciones farmacéuticas que los contienen, y estos compuestos para usar en el tratamiento de enfermedades proliferativas
PT3262071T (pt) * 2014-09-23 2020-06-16 H Hoffnabb La Roche Ag Métodos de utilização de imunoconjugados anti-cd79b
WO2017007658A1 (en) * 2015-07-07 2017-01-12 Rigel Pharmaceuticals, Inc. A combination for immune mediated cancer treatment
WO2017035234A1 (en) * 2015-08-24 2017-03-02 Epizyme, Inc. Method for treating cancer
EP3487878A4 (en) * 2016-07-20 2020-03-25 University of Utah Research Foundation CD229-CAR-T CELLS AND METHOD FOR USE THEREOF
CN109982687A (zh) * 2016-09-19 2019-07-05 梅制药公司 联合疗法
WO2018060833A1 (en) * 2016-09-27 2018-04-05 Novartis Ag Dosage regimen for alpha-isoform selective phosphatidylinositol 3-kinase inhibitor alpelisib
WO2018082444A1 (zh) * 2016-11-02 2018-05-11 叶宝欢 吡唑并嘧啶化合物作为pi3k抑制剂及其应用
KR20200041358A (ko) * 2017-08-14 2020-04-21 메이 파마, 아이엔씨. 병용 요법

Also Published As

Publication number Publication date
CA3109184A1 (en) 2020-02-20
EP3836935A1 (en) 2021-06-23
IL280726A (en) 2021-03-25
MA53236A (fr) 2021-06-23
MX2021001606A (es) 2021-04-19
US20210299134A1 (en) 2021-09-30
EP3836935A4 (en) 2022-09-14
BR112021002760A2 (pt) 2021-05-11
JP2021534115A (ja) 2021-12-09
SG11202101450VA (en) 2021-03-30
AU2019321432A1 (en) 2021-03-25
TW202021591A (zh) 2020-06-16
WO2020036999A1 (en) 2020-02-20
CN112888441A (zh) 2021-06-01

Similar Documents

Publication Publication Date Title
US12157735B2 (en) Compounds for targeted degradation of BRD9
US12037346B2 (en) Amino-substituted heteroaryls for treating cancers with EGFR mutations
CN107108637B (zh) 三唑并嘧啶化合物及其用途
JP6779870B2 (ja) 抗増殖性化合物及びその使用方法
EP3402795B1 (en) 5-substituted 2-(morpholin-4-yl)-1,7-naphthyridines
JP2021517116A (ja) 併用療法
JP6616411B2 (ja) 新規な、ｎｉｋ阻害剤としてのピラゾール誘導体
CN115443276A (zh) 吡啶并嘧啶酮衍生物及其作为芳烃受体调节剂的应用
KR20190058550A (ko) 병용 요법
KR20170113551A (ko) Irak 억제제로서 피리다지논 매크로사이클 및 이의 용도
ES2821102T3 (es) Derivados de azaquinazolincarboxamida
KR20200041358A (ko) 병용 요법
WO2022261159A1 (en) Tricyclic heterocycles as fgfr inhibitors
KR20210043635A (ko) B 세포 악성 종양의 치료
KR20210043637A (ko) 재발성 여포성 림프종의 치료
CN112839651A (zh) 联合疗法
ES2878585T3 (es) Compuestos de indazol para su uso en lesiones tendinosas y/o ligamentosas
RU2819642C1 (ru) Соединения азалактама в качестве ингибиторов hpk1
JP2025502326A (ja) デオキシシチジンキナーゼ阻害剤

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20210311

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20220811

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20250328

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20250531

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D